Fiala

Peptide library › Hormonal & fertility

Pasireotide

Also known as Signifor, Signifor LAR

FDA-approved drugHormonal & fertility

Somatostatin-like medicine for Cushing's disease and acromegaly when surgery hasn't worked.

What people use it for

What Pasireotide does in the body

A somatostatin analog that acts on more somatostatin receptor types than octreotide, including the one that controls ACTH, so it can lower cortisol in Cushing's disease.

Strength of evidence

Strong: Phase 3 trials in both conditions.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2012 (Signifor, Cushing's disease) and 2014 (Signifor LAR, acromegaly). Prescription only.

How it's taken

Route: Injection under the skin twice daily, or a monthly depot into a muscle

How long it lasts (half-life): About 12 hours

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Pasireotide privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Pasireotide in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Hormonal & fertility